UC Davis Health was one of about 120 trial sites selected worldwide to participate in the Phase 2/3 stage testing of the COVID-19 vaccine candidate known as BTN162, developed by Germany’s BioNTech and Pfizer Inc. The addition of this pivotal clinical trial adds even a more significant component to the university’s response to COVID-19. Now Davis, California—near Sacramento—is hosting the major clinical trial and 200 volunteers are needed. UC Davis’ Medical Center providers diagnosed and treated the first apparent case of COVID-19 in the United States, according to their recent news release. UC Davis Health represents the hub of medical research for Sacramento, California’s capital and rapidly growing metropolis.
UC Davis Health, according to David Lubarsky, vice chancellor of human health sciences and chief executive officer for UC Davis Health is “uniquely positioned to help with a possible breakthrough,” contributing to this pivotal study because 1) deep clinical trials expertise, 2) ability to expedite the recruitment of study volunteers, and 3) track record of engaging with minority communities that can translate to more diverse volunteers.
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).